INTRODUCTION
In Alzheimer's disease (AD) two main proteins form abnormal polymers (1) . The extracellular amyloid plaques consist largely of polymerized Aβ-peptide while the intracellular neurofibrillary tangles are made from the microtubule-associated protein tau (2) . These insoluble aggregates or their oligomeric precursors are involved in the neuronal degeneration. The distribution of the neurofibrillary changes can be used for the diagnosis and staging of AD (3), it is based on the appearance of tau in an aggregated state which in addition is chemically modified (phosphorylation, truncation, glycation). Whether these modifications are the cause or merely byproducts of neuronal degeneration has been a matter of debate. For example, different kinase pathways have been considered Screening of tau aggregation inhibitors by thioflavin-S assay: PHF formation was monitored by a thioflavin-S fluorescence assay (22) . Using an automated pipetting system (Cybi-Well, CyBio, Jena, Germany) 50 mM NH 4 Ac, 10 µM protein (K19), 60 µM compound and 2.5 µM heparin were mixed in 50 µl volume in a 384 well plate (black microtiter 384 plate round well, ThermoLabsystems, Dreieich, Germany) and incubated overnight at 37 °C. As a control the protein was replaced with H 2 O to measure the possible fluorescence of the compounds. After incubation with the compounds thioflavin-S was added to a final concentration of 20 µM and the signal was measured at excitation of 440 nm and emission of 521 nm in a spectrofluorimeter (Ascent; Labsystems, Frankfurt). To measure the inhibition of PHF assembly and disassembly of PHFs we chose compound concentrations of 200 µM, 60 µM, 10 µM down to 10 pM at a 10 µM concentration of tau.
All measurements were carried out three times.
Tryptophan fluorescence spectroscopy:
The fluorescence experiments were performed on a Spex Fluoromax spectrophotometer (Polytec, Waldbronn, Germany) using 3 mm × 3 mm microcuvettes from Hellma (Mühlheim, Germany) with 20 µl sample volumes.
Tryptophan emission was scanned from 300 to 450 nm at fixed excitation wavelength of 290 nm. For the inhibition assay, 60 µM compounds were incubated with constructs K19/Y310W, K18/Y310W or K18∆K280/Y310W (10 µM) and heparin (2.5 µM) in PBS, pH maximum (~354 nm for soluble tau, ~340 nm for aggregates).
Filter trapping assay:
Aggregates of tau were trapped by filtration through a PVDFmembrane (pore diameter 0.45 µm, Schleicher and Schuell, Düren, Germany) adapted to 96-well dot blot apparatus. The PVDF-membrane was wetted with methanol and rinsed with PBS-buffer before insertion. Samples were pipetted into 100 µl of PBS and filtered.
The membrane was washed three times with PBS before taking it out of the apparatus and blocked with 5% milk powder in PBS for 30 min in a rotational shaker at RT. The polyclonal antibody K9JA was used as primary antibody and incubated at a dilution of 1:20.000 at RT for one hour. A secondary anti-rabbit antibody conjugated with horseradish peroxidase (Dako, Hamburg, Germany) was diluted 1:2000 and incubated for 30 min at 37 °C. After three times washing with TBS-Tween the signal was detected using the ECL system (Amersham Pharmacia). Pictures were taken with the digital gel documentation system Fuji film BAS3000 (Raytest, Straubenhardt, Germany) and quantified with the AIDA-software package (Raytest, Straubenhardt, Germany).
Electron microscopy: Protein solutions diluted to 0.1-10 µM were placed on 600-mesh carbon-coated copper grids for 1 min and negatively stained with 2 % uranyl acetate for 45 sec. The specimens were examined in a Philips CM12 electron microscope at 100 kV (Eindhoven, Netherlands).
Light scattering analysis of tau-induced microtubule assembly: Microtubule assembly was monitored by light scattering at 350 nm in a Tecan spectrophotometer model Safire (Tecan, Crailsheim, Germany). Tau protein (10 µM) was mixed with tubulin dimer (30 µM) and GTP (1 mM) at 4°C in polymerization buffer (100 mM Na-PIPES pH 6.9, 1 mM EGTA, (60 µM) were added last. After rapid mixing, the samples were pipetted into a Greiner transparent flat bottom 384 well plate (4 mm path length) prewarmed at 37°C. The reaction was started by incubating the cooled reaction components at 37°C. The assembly of tubulin into microtubules was monitored by a change in turbidity. Three parameters were extracted from curves. The maximum turbidity at steady state, the rate of assembly, and the lag time between the temperature jump and the start of the turbidity rise.
Inducible expression of tau in N2a cells:
The generation of the cell model is described in detail elsewhere. Briefly, tau construct K18∆K280 was expressed in the mouse neuroblastoma cell line N2a in an inducible manner under the control of the reverse tetracycline-controlled transactivator (rtTA) (23) . The cells were cultured in MEM medium with 10% fetal calf serum, 2 mM glutamine and 0.1% nonessential amino acids.
Expression of K18∆K280 was induced by adding 1 µg doxycyclin per 1 ml medium. The induction was continued over 7 days and the medium was changed 3 times in 2-day intervals, complemented with doxycyclin or with doxycyclin plus tau aggregation inhibitors.
Assays of tau aggregation in N2a cells:
The levels and solubility of the K18∆K280 tau protein were determined by the method of Greenberg and Davies (24) which makes use of the insolubility of protein aggregates in cell homogenates after treatment with sarkosyl.
The supernatant and sarcosyl-insoluble pellets were analyzed by Western blotting with the pan-tau antibody K9JA and analyzed by densitometry. Aggregation of tau in cells was tested by the fluorescence of thioflavin-S. ThS signals were scored in three independent fields containing 40 cells each.
RESULTS
(a) Compounds sharing a core structure of hydroxyanthraquinone inhibit PHF assembly.
We tested 200.000 compounds in a high throughput screen for their capability of interfering with the aggregation of tau protein. Several members of the class of hydroxyanthraquinone and related structures were found (Fig. 1A) . They all share a tricyclic aromatic ring system with some modifications. Emodin and compound PHF016 belong to the class of hydroxyanthraquinones, whereas compound PHF005 represents a benzophenone derivative. Daunorubicin and adriamycin are enlarged with a further ring system to the naphthacendione structure and a sugar moiety.
The initial screening for inhibition of PHF aggregation was performed with the three repeat tau construct K19 (Fig. 1B) . This was chosen because it aggregates reliably at low µM concentrations in the presence of the polyanionic cofactor heparin and resembles Alzheimer's PHFs in terms of fiber morphology and beta sheet content (19, 25) . The results described here were obtained by measuring the extent of aggregation via the fluorescence of ThS (22) . This is based on the binding of ThS to fibers containing β-structure which causes a change in the fluorescence spectrum (29) . In the screen we performed polymerization of K19 in the presents and absence of inhibitors. Hits were defined by a >90% decrease of the ThS-signal compared with the control reaction without compounds.
This level of inhibition was reached by 1266 compounds (0.6 % of the cohort). These were further tested for their ability to dissolve preformed PHFs, a more stringent criterium. 77 compounds were able to reduce the PHF specific signal ThS fluorescence by more than 80%. To confirm the data we also used the four repeat constructs K18, K18∆K280 and the related full length isoforms htau23 (three repeat, no inserts) and htau24 (four repeats, no inserts).
The five compounds discussed here are able to inhibit the transition from soluble to aggregated K19 protein, but they differ in their efficiency. Using fixed protein concentrations of K19 we tested the compounds in a concentration range from 10 pM to 200 µM ( Fig. 2A) and determined IC 50 values (Table 1) . Inhibitory effects begin to appear around 0.1 µM (ratio of protein to compound = 100) and reach nearly complete inhibition at 100 µM compound (ratio protein to compound = 0.1). The curves of Fig values down to the sub-µM range. However, the decay of the curves of K18 is more gradual than those of K19, extending over 3-4 orders of magnitude (compare Fig. 2A ).
This suggests that the filaments made from the 3-repeat construct K19 are more stable and more homogeneous than those made from the 4-repeat K18, possibly because K18 contains two nucleating hexapeptide motifs.
The study was then extended to the natural three and four repeat isoforms htau23 and htau24 (Fig. 1B) . PHF formation of these proteins was assayed in the presence of 0.1, 1, 10 and 60 µM compound (Fig. 2C, D) . Again a clear dose dependent inhibition was observed. In this case the filaments from the 3-repeat isoform htau23 are somewhat less stable than those from the 4-repeat htau24. The compounds can be subdivided into two groups. For htau23 the more effective compounds are adriamycin, daunorubicin and emodin which are capable to inhibit PHF formation about 50% at 0.1µM and ~90 % at 60 µM. Compounds PHF016 and PHF005 are less inhibitory, they show only a slight effect at low concentration and a moderate one (~60%) at 60µM. For htau24 the ranking is roughly the same, with PHF016 and PHF005 showing little inhibitory activity.
All the polymerization reactions carried out so far used heparin as a cofactor for inducing PHF assembly because otherwise the process would be impracticably slow (26, 27) . In order to rule out a potential influence of heparin on the efficiency of the compounds we used the 4-repeat construct K18∆K280 which carries one of the mutations observed in frontotemporal dementia (28) and is capable of aggregating into PHFs without a polyanionic cofactor (25) (Fig. 2E, F) . Overall the IC 50 values of assembly inhibition are higher or equal for K18∆K280 filaments than for K18wt (suggesting that K18wt is more easily disrupted than the mutant), but the values are comparable with or without heparin, indicating that heparin does not greatly influence the interference between the compounds and PHFs.
In order to exclude a possible distortion of the data by the ThS dye we wanted to confirm the results by a tryptophan fluorescence assay (30) . It allows the detection of the molecular environment of a tryptophan introduced instead of tyrosine 310 whose emission maximum is sensitive to the burial in a more hydrophobic surrounding upon PHF formation. We therefore created the mutants K19/Y310W, K18/Y310W and K18∆K280/Y310W (Fig. 1B) that contain a single tryptophan within the core of the PHF structure. In the soluble protein the emission maximum lies at ~354 nm (dashed line), whereas it shifts to 340 nm upon PHF formation (dotted line) (Fig. 3A , first and second entry). The emission peak can be shifted back by incubation at high concentrations of GuHCl which is due to the disassembly of the PHFs (Fig. 3A , fourth entry).
In the Trp fluorescence assay the inhibition of PHF assembly becomes apparent if the emission maximum of Trp310 remains higher than that of the control without any compound, because Trp310 remains in a more solvent-accessible environment. The three repeat tau construct K19/Y310W (at 10 µM) is prevented from aggregation by ~90% by all compounds at 60 µM (Fig. 3A , note that entries 5-9 retain their values around 354 nm, similar to the control #1). By contrast the four repeat tau construct K18/Y310W is inhibited to this high extent only by PHF005 (Fig. 3B , entry #9). Emodin, daunorubicin and adriamycin can prevent PHF formation to about 70% at 60 µM (Fig. 3B , entries #5, 6, 7), whereas PHF016 achieves only 25% inhibition (#8). The trend becomes even more pronounced in the case of K18∆K280/Y310W, where all compounds show a lower activity (Fig. 3C ). The internal ranking stays roughly the same as with K18; PHF005 (#9) is the best, PHF016 (#8) the worst inhibitor. Emodin, daunorubicin and adriamycin (#5, 6, 7)
showed a level of ~30-50% inhibition. The apparent degrees of inhibition differ somewhat between the ThS fluorescence and the intrinsic Trp fluorescence assays. One likely explanation is the different origin of the signal. In the ThS assay the dye has to bind to the filaments, which requires a minimal length of the fibers. The tryptophan fluorescence assay depends on the local surrounding of the residue and is therefore less dependent on the length of the filaments.
(b) PHFs can be dissolved by inhibitor compounds
Inhibiting the aggregation is one important aspect of a potential therapeutic compound, but even more important may be the ability to dissolve preformed filaments. We used the ThS assay to analyze this aspect with PHFs made from the repeat domain constructs K19 and K18 as well as from isoforms htau23 and htau24, containing 3 or 4 repeats. The disassembly of K19 filaments (Fig. 2G ) follows similar concentration dependence as the inhibition experiment, with similar or slightly higher DC 50 values than the corresponding IC 50 concentrations (low µM range, Table 1 ). K18 filaments show equal or slightly higher DC 50 values, i.e. the 4-repeat constructs are more resistant to the compounds (Fig. 2H) .
Here, too, the concentration dependence for K19 is steeper than for K18 (compare Fig. 2G and Fig. 2H ), similar to that of assembly inhibition ( Fig. 2A and Fig. 2B ), arguing for more heterogeneity in the K18 filaments.
PHFs from the full length 3-repeat isoform htau23 can also be disassembled, albeit with lower efficiency (Fig. 2I) . Emodin, daunorubicin and adriamycin (DC 50 range 7.0-13 µM) are more potent than PHF016 and PHF005 (DC 50 >60µM), consistent with the ranking in the assembly inhibition assay (Fig. 2C ). By contrast, in the case of 4-repeat htau24 all compounds have a low efficiency (Fig. 2J) , the best values are achieved for PHF016 and PHF005 (DC 50 values in the 10-40 µM range). Thus 4-repeat full length tau appears to be more stable than 3-repeat tau, both in the assembly inhibition and in the disassembly assay.
The influence of heparin was tested by comparing the disassembly of filaments made from K18∆K280 without or with heparin ( Fig. 2K and Fig. 2L , Tab. 1). As in the assembly inhibition assay the results are broadly comparable, showing that heparin does not have a major influence on the results (DC 50 values range from 1-7.5 µM).
As controls we performed the disassembly experiments with the tryptophan assay (Fig. 3 D -F) at compound concentrations of 60 µM. In the tryptophan assay the compounds are able to dissolve K19 filaments (Fig. 3D ), except daunorubicin (Fig. 3D, entry #6 ). All other compounds yield emission maxima after treatment around 350-353nm, close to the value of soluble tau, indicating a disassembly efficiency of about 80-90%. In the case of K18 filaments (Fig. 3E ) all compounds show a significantly lower efficiency of depolymerization, only PHF005 is a strong inhibitor under these conditions (80%), whereas emodin, adriamycin and PHF016 exhibit not more than 10% efficiency. This ranking is consistent with the assembly inhibition assay (Fig. 3B) . In the case of K18∆K280 (Fig. 3F ) the efficiency of disassembly is further reduced, but the ranking remains comparable to that of K18 (compare Fig. 3E ), as well as to the assembly inhibition assay (Fig. 3C) . In these cases, PHF005 remains the most potent agent for depolymerizing PHFs (entry #9).
As a third method we used a filter trap assay (Fig. 4) . This assay monitors aggregated tau trapped on a membrane filter, whereas soluble protein is washed through. Therefore the technique preferably detects larger filaments, similar to the ThS assay. The compounds show similar disassembly activities as the ThS assay; emodin was most effective with a DC 50 of ~0.5 µM.
All the results were confirmed by electron microscopy. Fig. 5A and B illustrates examples of PHFs in the process of disassembly after overnight incubation with inhibitors. Filaments are seen in various stages of shortening or breaking, and the background contains numerous aggregates of undefined structure.
The general rule emerging from these experiments is that the compounds are more efficient in inhibiting de novo formation of PHFs than in depolymerizing preformed ones. This is revealed by the ThS fluorescence assay, by the filter trap assay, by the tryptophan fluorescence shift assay and by electron microscopy and holds for all tau constructs and isoforms.
(c) Submicromolar concentrations dissolve PHFs at prolonged incubation times
For a potential therapeutic use one would like to have compounds which show activity both in inhibiting the de novo aggregation as well as in depolymerizing preexisting aggregates at sub-micromolar concentrations. Our depolymerization data were typically obtained after 12 hours of incubation, but we were also interested in the effects of longer incubation times and lower compound concentrations. Fig. 6 shows the time course of disassembly (by the ThS assay) of K19 PHFs in the presence of 0.5 µM adriamycin or PHF005 during 28 days. Nearly no effects are seen after 12 hours, consistent with the earlier experiments ( Fig. 2G ) but interestingly the depolymerization still continues and results in a final depolymerization of ~20-30% after 28 days. This suggests that even low concentrations of inhibitors can be used for disassembly at prolonged incubation times.
(d) Aggregation inhibitors do not interfere with tau-microtubule binding
The repeat domain of tau is not only important for PHF aggregation but also for the physiological function of microtubule binding. We therefore considered the possibility that the compounds inhibit both of these functions. Microtubule polymerization assays were performed with or without compounds (Fig. 7) in a modified assay format. Tubulin (at 30 µM) without tau serves as a negative control which is unable to self-assemble into microtubules because it is below the critical concentration. In the presence of tau (10 µM) tubulin polymerizes within 4 min. In the presence of compounds (60 µM) the rate and extent of polymerization are not significantly affected, except for daunorubicin. The same is true for Congo Red, an Aβ fiber inhibitor (31), used as a further control. These data suggest that the tested compounds influence specifically the pathological aggregation of tau protein, but not its interaction with microtubules.
(e) Cell models of tauopathy can be rescued by inhibitors
A crucial test for the inhibitors is their effect in cell models of tauopathy. To address this question we generated a neuroblastoma (N2a) cell line which allows inducible expression of the tau construct K18∆K280 under the control of the tet-on transactivator. This construct was chosen because it contains the FTDP17 mutation ∆K280 in the 4-repeat domain K18 which promotes the formation of β-structure and therefore aggregates readily in vitro, even without polyanionic inducers (25, 32) . Expression of tau was initiated with 1 mg/ml doxycyclin. The effect of aggregation inhibition was observed by adding the inhibitor emodin (15 µM). After 3-7 days the cells were tested for tau aggregation and thioflavin S fluorescence. Fig. 8A shows Westernblots of the cell extract after 7 days. Aggregated tau was separated from soluble tau by sarkosyl extraction, followed by pelleting. The pellet of the untreated control (-Emo) shows the typical "smear" at higher molecular weight which is characteristic of aggregation in Alzheimer's disease (Fig. 8A, lane 2) . However, emodin strongly suppresses the aggregates, leaving tau mostly in the soluble state (Fig. 8A, lane   4) . Quantification of the sarkosyl-insoluble fraction shows a 5-fold reduction by emodin, from 14% of the total cellular tau down to 3% (Fig. 8B) . Similar results were obtained by staining the cells with ThS (to show aggregated material) and with an antibody against total tau (to show the level of tau expression) (Fig. 8D) . The level of tau expression was comparable without or with emodin (compare Fig. 8D left, top and bottom) . However, whereas the ThS signal was strong in the tau expressing cells, it became very weak in the presence of emodin, consistent with the absence of aggregates (Fig. 8D middle, top and bottom). There were fewer ThS responsive cells, and fluorescence intensity was much lower as well. The merged images illustrate that a large fraction of cells contain visible aggregates (green-yellow in superposition), whereas the ThS signal was hardly visible in the emodin-treated cells (Fig. 8D, right, quantification in Fig. 8C ). These experiments show that tau aggregation inhibitors have the potential to reduce the level of aggregation without affecting the expression of tau as such, and that they are able to rescue cells from the toxic effects of tau aggregates.
DISCUSSION
The anomalous aggregation of proteins into amyloid fibers is common to diverse human diseases, often related to advanced age. Factors contributing to this accumulation include the increased rate of protein misfolding, generation of amyloidogenic peptides, underactivity of repair systems (chaperones) and waste disposal (ubiquitin-proteasome system), or loss of energy supply and antioxidant defense mechanisms (impairment of mitochondria and peroxisome functions). There is a debate on whether fully aggregated proteins or smaller precursors (oligomers) cause cellular damage, but emerging evidence indicates that lowering the production or removal of the aggregates is one pathway towards alleviating the disease state (33) (34) (35) . It is thus of interest to understand the pathway of aggregation and to identify and optimize inhibitors that might be of therapeutic value.
Despite the differences between the disease-causing proteins the aggregation is often based on a similar principle, the formation of cross-β structure where extended polypeptide segments embedded in β-sheets are aligned perpendicularly to the filament axis. The sheets provide binding surfaces for various dyes (Congo red, thioflavin-S). The conditions for cross-β aggregation have been studied for various short peptides (36) (37) (38) (39) (40) (41) . Important parameters include (a) the conformation of the polypeptide as an extended chain, capable of forming hydrogen bonds with parallel or antiparallel neighboring chains, (b) apolar or aromatic side chains at certain positions which promote the stacking of β-sheets by hydrophobic interactions, and (c) charged residues which promote electrostatic interactions and in addition provide guidance for the regular buildup of filaments. By implication, the aggregation of filaments can be inhibited by inserting β-breaking residues such as proline into the sequence, by disrupting the hydrophobic glue between sheets (e.g. mutation, oxidation, phosphorylation of residues), by neutralizing Coulomb interactions (resulting in undirected amorphous aggregation rather than filaments). These considerations apply to the β-forming core sequence; in the case of larger proteins, where only a small fraction of the sequence is engaged in the cross-β core, the remainder of the protein will determine whether the core peptide becomes accessible for interaction with other core peptides (42, 43) . Thus, conceptually one has to distinguish between aggregation inhibitors that target the cross-β core directly, or the conformation of the protein which determines whether it is aggregation-competent or not. The first type of inhibitor would be expected to crossreact with several types of amyloid, whereas inhibitors of the second type could be specific for one particular protein.
In Alzheimer's disease there are two types of anomalous protein aggregates, β-amyloid fibers formed from the Aβ peptide, and PHFs formed from tau protein. In the case of β-amyloid the cross-β structure of the fibers has been recognized early on because it dominates the filament structure (44, 45) . With tau the nature of the PHFs was less obvious because tau is mostly a "natively unfolded" protein. Only a small fraction is engaged in forming the cross-β backbone of the PHF core whose signature tends to be masked in biophysical studies of PHFs. The cross-β structure of PHFs is centered on one or two hexapeptide motifs in the repeat domain of tau (19) . Therefore one would expect that compounds which disrupt β-structure might also inhibit tau aggregation. In addition, the core of the PHFs is formed from the repeat domain and is thus larger than the hexapeptide motifs. One would also expect other types of inhibitory compounds acting on different parts of the protein, thereby altering conformations or other properties. Such compounds would be interesting for a tau-specific inhibition of aggregation.
In order to identify inhibitors of PHF aggregation we screened a library of 200,000 compounds. Promising compounds were probed by secondary assays, such as sedimentation and electron microscopy, and the example of one subclass (anthracenes) is described here. We also developed a cell model of tau aggregation in order to probe the effects of tau aggregation inhibitors. We wanted to answer several questions:
• What types of compounds can inhibit the aggregation of tau? These PHF-inhibitor compounds could be useful in preventing aggregation and thus delaying the disease process.
• Are these compounds also effective in disassembling pre-assembled PHFs? Such PHF-breaker compounds might help to reverse the disease process.
• Are compounds that inhibit tau aggregation in vitro also active in a cellular environment?
• Is the inhibition of aggregation beneficial for cells?
The last two questions are important in the light of tau's presumend functions in cells. It is a priori not clear how the balance between aggregated and soluble tau would affect the physiology of cells. Tau's best-known function is to stabilize axonal microtubules (which is considered positive for the cell, and which is deficient in Alzheimer's disease). However, an increase in the level of tau can impair axonal transport (46) , and it can interfere with the dynamic instability of microtubules that is necessary for neuronal survival and axonal growth (47) . These two properties of tau could, in principle, cause damage to cells independently of aggregation.
Many of the inhibitory compounds found in the initial screen contain ring structures. This might seem surprising, considering that tau is a hydrophilic molecule with very few aromatic residues. Part of the explanation is that ring structures are abundant in the compound library, but the likely structural interpretation is that these inhibitors interrupt the β-structure around the hexapeptide motifs of tau, for example by intercalating between the hydrophobic residues and thus disrupting the interface between two neighboring sheets.
Other reported inhibitors of tau aggregation have ring structures as well, such as phenothiazines (48) or a benzothiazolidine derivative (49) . We also note that some compounds that have shown up in our screen have been found in other screens designed for the inhibition of other amyloidogenic peptides like Aβ (e.g. daunomycin, (50)) or transthyretin (e.g. a doxorubicin derivative, (51)).
When considering the origins of tauopathies the issue of phosphorylation deserves special attention. Due to its unfolded nature and numerous serines and threonines, the protein can be phosphorylated at many sites and by many kinases. Some sites cause the detachment of tau from microtubules, others may control interactions with partners (e.g. docking sites for kinases or phosphatases). In all tauopathies, tau is hyperphosphorylated. Whether or not this promotes aggregation is a matter of debate, but if one makes that assumption it would be natural to reduce the activity of the responsible kinases (or enhance the activity of phosphatases). Thus, in current efforts to find inhibitors of tauopathy one can distinguish two approaches, screens for inhibitors of kinase signalling (52) (53) (54) and aggregation inhibitors (49) . Our own experimental evidence suggests that phosphorylation in vitro does not promote tau aggregation but rather reduces it (6), and therefore we decided to search directly for aggregation inhibitors.
Finally, the crucial question is: Can the application of tau aggregation inhibitors prevent or rescue an organism from tauopathy? This issue can be addressed by using cell models of tauopathy. The development of suitable models has been slow since overexpression of tau per se does not lead to aggregation, due to tau's high solubility and phosphorylation.
However, following the discovery of tau mutations in FTDP-17 several cell models have been created that express tau mutants (e.g. (54) (55) (56) . In our cell model we have combined two features: One is the choice of the mutation ∆K280 because this strongly promotes the aggregation of tau. The second is the inducible expression in a neuroblastoma cell line (N2a) because this allows one to ask whether tau aggregates emerge with time after induction and to check whether they disappear when the tau expression is switched off again. In the context of the present study, the important point is that tau aggregates can be made to disappear by treating the cells with an inhibitor. This suggests that pharmacological approaches to contain the aggregation of tau could be a valid approach for tauopathies such as Alzheimer's disease.
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We would like to thank Sabrina Hübschmann, Anja Reichelt and Bianca Wichmann for excellent technical assistance. We are grateful to Merck For disassembly experiments tau constructs and isoforms K19, K18, hTau23, hTau24 (10 µM) were first aggreated into PHFs as described and the polymers separated from the soluble tau by centrifugation of 1h at 100,000g, resolved and then exposed to the inhibitors overnight at 37°C at the indicated concentrations (range 0.001-200 µM). The compounds are capable of disassembling PHFs with varying efficiencies (see Table 1 ). (G) construct K19, (H) K18, (I) htau23, (J) htau24, (K) K18∆K280 (no heparin), (L) K18∆K280 (with heparin). All measurements were performed in triplicates. Fluorescence emission maximum of the single tryptophan W310 inserted by site-directed mutagenesis into tau constructs K19 (Fig. 3A) , K18 (Fig. 3B) and K18∆K280 (Fig. 3C) . (Fig. 3A) , but the 4-repeat construct K18/Y310W (Fig. 3B) , and its mutant K18∆K280/Y310W (Fig. 3C) , mutant are much less responsive to the inhibitors.
Disassembly of preformed PHFs made from (D) K19/Y310W, (E) K18/Y310W, (F) K18∆K280/Y310W induced by inhibitor compounds. Note that PHF aggregation is largely reversible for K19 (except for daunorubicin), but only partially for K18 and K18∆K280. All measurements were done in triplicates. 
